Convertibles sold at a 10% discount convert at 20% discount to market
By Devika Patel
Knoxville, Tenn., July 20 - Northwest Biotherapeutics, Inc. settled a $1.1 million private placement of convertible notes on July 16, according to an 8-K filed Friday with the Securities and Exchange Commission.
The note matures on Jan. 16, 2013 and was sold at a 10% original issue discount. It converts to common stock at a 20% discount to the market price at the time of conversion.
The investors also received warrants for 1.25 million shares. Each four-year warrant is exercisable at $0.40, an 81.82% premium to the July 19 closing share price of $0.22.
Northwest is a development-stage biotechnology company based in Bothell, Wash.
| Issuer: | Northwest Biotherapeutics, Inc.
|
| Issue: | Convertible note
|
| Amount: | $1.1 million
|
| Maturity: | Three years
|
| Price: | 10% discount
|
| Conversion price: | 20% discount to the market price at the time of conversion
|
| Warrants: | For 1.25 million shares
|
| Warrant expiration: | Four years
|
| Warrant strike price: | $0.40
|
| Announcement date: | July 20
|
| Settlement date: | July 16
|
| Stock symbol: | OTCBB: NWBO
|
| Stock price: | $0.22 at close July 19
|
| Market capitalization: | $35.82 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
